Findings

What do systematic reviews say?

84 questions · 87 findings · 23 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 21 · 24.1%GRADE not reported 0 · 0%Very low 29 · 33.3%Low 26 · 29.9%Moderate 11 · 12.6%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Related · question page
- Intranasal steroid drops vs placebo · Prevalence of parosmia
  Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Intranasal steroid spray vs no intervention/placebo · Presence of normal olfactory function Assessed by participants as a score of 10 on a VAS (range 0 to 10) ≤ 4 weeks
  Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  RR 1.19 [0.85, 1.68]
  1 study · 100 participants
  Very low
Related · question page
- Positive pressure therapy vs placebo · Change in functional profile in the 8 weeks before and after 4 weeks of treatment
  Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Moderate
Related · question page
- Intranasal steroid spray vs no intervention/placebo · Prevalence of parosmia
  Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Intranasal steroid drops vs placebo · Presence of normal olfactory function Assessed by participants > 4 weeks to 3 months
  Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  RR 1 [0.89, 1.11]
  1 study · 248 participants
  Low

Positive pressure therapy vs placebo

Improvement in vertigo frequency · Ménière’s disease

Positive pressure therapy showed no clear difference in improvement in vertigo frequency compared with placebo (low certainty).

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.19 [0.82, 1.71]
1 study · 77 participants
Low

Positive pressure therapy vs placebo

Change in vertigo (global score) · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Very low

Positive pressure therapy vs placebo

Change in vertigo frequency · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 202 participants
Very low

Positive pressure therapy vs placebo

Serious adverse events · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Positive pressure therapy for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Positive pressure therapy vs placebo

Proportion of days with vertigo in 4 weeks: vertigo scores > 2 · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Moderate

Positive pressure therapy vs placebo

Cumulative vertigo scores after 4 months · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Positive pressure therapy vs placebo

Vertigo days in 4 months: vertigo scores > 2 · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Positive pressure therapy vs placebo

Vertigo (frequency) · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Positive pressure therapy vs placebo

VAS scores for vertigo after 8 weeks of treatment · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Positive pressure therapy vs placebo

Loss or gain of hearing in 4 months (dB) · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Moderate

Positive pressure therapy vs placebo

Cumulative activity score · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate

Positive pressure therapy vs placebo

Change in functional profile in the 8 weeks before and after 4 weeks of treatment · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Positive pressure therapy vs placebo

Days of sick‐leave at 1 year · Ménière’s disease

1 finding from 1 review

Positive pressure therapy for Ménière's disease or syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 125 participants
Moderate

Intranasal steroid spray vs placebo or no intervention

Presence of normal olfactory function · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

It is very uncertain whether intranasal steroid spray changes presence of normal olfactory function Assessed by participants as a… compared with no intervention/placebo (very low certainty).

2 findings from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 1.19 [0.85, 1.68]
1 study · 100 participants
Very low
Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 2.31 [1.16, 4.64]
1 study · 77 participants
Very low

Intranasal steroid drops vs placebo

Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 1 [0.89, 1.11]
1 study · 248 participants
Low

Intranasal steroid drops vs placebo

Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid spray vs placebo or no intervention

Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Endolymphatic sac decompression vs placebo (sham surgery)

Improvement in vertigo (complete resolution) at 6 to ≤ 12 months (12 months) · Ménière’s disease

It is very uncertain whether endolymphatic sac decompression changes improvement in vertigo (complete resolution) at 6 to ≤ 12 months (12… compared with placebo (sham surgery) (very low certainty).

1 finding from 1 review

Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
RR 1.3 [0.86, 1.96]
1 study · 30 participants
Very low

Endolymphatic sac decompression vs placebo (sham surgery)

Improvement in vertigo · Ménière’s disease

1 finding from 1 review

Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Endolymphatic sac decompression vs placebo (sham surgery)

Serious adverse events · Ménière’s disease

The review found no eligible studies for this question.

1 finding from 1 review

Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found